177Lu-DOTA-EB-TATE

DRUG3 trials

Sponsors

Peking Union Medical College Hospital, Molecular Targeting Technologies, Inc., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions

Neuroendocrine TumorsThyroid Cancer

Phase 1

177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Peking Union Medical College HospitalNeuroendocrine Tumors

Start: 2017-04-30End: 2018-05-01Target: 30Updated: 2017-10-12

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

RecruitingNCT05475210

Molecular Targeting Technologies, Inc.Neuroendocrine Tumors

Start: 2022-06-18End: 2025-03-30Target: 9Updated: 2024-03-13

177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

Not yet recruitingNCT06991738

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Thyroid Cancer

Start: 2026-04-09End: 2032-08-01Target: 18Updated: 2026-04-06